/ Side by side
Retatrutide vs Survodutide
A neutral, side-by-side look at Retatrutide and Survodutide: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Retatrutide
Reta · Triple-G · LY3437943
Full profile →Survodutide
BI 456906
Full profile →| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~6 days, subcutaneous | ~6-7 days, subcutaneous |
| Common vial | 5, 10, 15, 20, 30 mg | 5, 10, 15 mg |
| Reference | Verified | Verified |
What is Retatrutide?
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration.
Sources
- Jastreboff et al., NEJM 2023 (phase 2 obesity)
- Nature Medicine 2024 (phase 2a MASLD)
What is Survodutide?
An investigational dual glucagon and GLP-1 receptor agonist with high albumin binding, studied in trials for obesity and metabolic-associated liver disease. Its half-life supports once-weekly administration.
Sources
- Zimmermann et al., Mol Metab 2022
- J Hepatology 2024 (cirrhosis PK)
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.